Eleven Apellis Pharmaceuticals insiders, including top executives, sold shares worth $2.86 million, raising investor curiosity. Despite recent stock declines, Apellis’ vision is strong with its Syfovre therapy—the first approved treatment for geographic atrophy—in both the U.S. and Australia. Analysts remain optimistic, suggesting